8 November 2025
Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion
Advising firms
Deal team
17 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | Capital Markets | Not stated |
| Andrew Blumenthal Lead | Latham & Watkins LLP | Partner | Capital Markets | Not stated |
| Ian Lachow | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Steve Hess | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Cheston Larson | Latham & Watkins LLP | Partner | corporate | Not stated |
| Michael Sullivan | Latham & Watkins LLP | Partner | corporate | Not stated |
| Sterling Swift | Latham & Watkins LLP | Associate | corporate | Not stated |
| Samantha Wang | Latham & Watkins LLP | Associate | corporate | Not stated |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | derivatives | Not stated |
| Sloan Ungerman | Latham & Watkins LLP | Associate | derivatives | Not stated |
| Daniel Weiss | Latham & Watkins LLP | Associate | derivatives | Not stated |
| Bora Bozkurt | Latham & Watkins LLP | Partner | tax | Not stated |
| Jack Santoro | Latham & Watkins LLP | Associate | tax | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA regulatory | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare regulatory | Not stated |
| Darryl Steensma | Latham & Watkins LLP | Counsel | intellectual property | Not stated |
| Kristina Funahashi | Latham & Watkins LLP | Associate | intellectual property | Not stated |
Stated terms
- Stated value
- USD 1.30bn (US$1.3 Billion)
- What the figure measures
- Issue size
- Client
- initial purchasersUnderwriters
- Counterparties
- Halozyme Therapeutics, Inc. (Issuer)